Stock comparison

ABBVvsGILD

AbbVie IncvsGilead Sciences Inc. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.

ABBV

AbbVie Inc

$200.95

-12.05%

Biotechnology$362.8BNYSE

GILD

Gilead Sciences Inc

$133.64

+10.12%

Biotechnology$173.4BNASDAQ

60-day price, rebased to 100

ABBV -8.25% · GILD -6.47%

Round-by-round

ABBV 2·GILD 4

EdgeGILD

Valuation upside

-48.60% vs -27.50% to DCF fair value

EdgeGILD

Balance-sheet strength

Altman Z 2.25 vs 4.47

EdgeGILD

Fundamental quality

Piotroski 7.00 vs 8.00 (of 9)

EdgeABBV

Growth + margins

Rule-of-40 37.70 vs 34.50

EdgeGILD

60-day momentum

-8.25% vs -6.47% price return

EdgeABBV

Market-cap liquidity

$362.8B vs $173.4B

Verdict

Across6categories,GILDtakes the edge with4wins to2. Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.

Backtest a strategy onABBVorGILD

Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.